Literature DB >> 22002703

[Squamous cell carcinoma of the esophagus].

K Ott1, L Sisic, M Büchler.   

Abstract

The prognosis of locally advanced squamous cell carcinomas (SCC) of the esophagus after surgery only is poor. Therefore a definitive chemoradiotherapy (RCTx) was also discussed as the therapy of choice. Besides tumor biology, patient-related factors, such as alcohol and nicotine abuse increase the perioperative mortality and morbidity. Multimodal treatment can improve the outcome in comparison to surgery alone. A recently published meta-analysis confirmed that preoperative RCTx followed by surgery improves the prognosis compared to surgery alone in SCC of the esophagus. After chemotherapy this effect is less pronounced. Patients with a complete histopathological response (pCR) after preoperative RCTx have a 5-year survival rate of more than 55% and a low probability of local recurrence. However, a pCR cannot be predicted neither by negative biopsy nor by negative FDG-PET uptake after RCTx. Up to now FDG-PET has shown a low impact for response prediction or therapy modification in SCC of the esophagus in clinical studies. Responding patients should be transferred to surgery after preoperative treatment, because of a reduced perioperative morbidity and mortality and improved prognosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002703     DOI: 10.1007/s00104-011-2128-2

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  28 in total

Review 1.  The importance of PET in the diagnosis and response evaluation of esophageal cancer.

Authors:  K Ott; W Weber; J-R Siewert
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

2.  Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.

Authors:  Mark van Heijl; Jikke M Omloo; Mark I van Berge Henegouwen; Otto S Hoekstra; Ronald Boellaard; Patrick M Bossuyt; Olivier R Busch; Hugo W Tilanus; Maarten C Hulshof; Ate van der Gaast; Grard A Nieuwenhuijzen; Han J Bonenkamp; John Th Plukker; Miguel A Cuesta; Fiebo J Ten Kate; Jan Pruim; Herman van Dekken; Jacques J Bergman; Gerrit W Sloof; J Jan van Lanschot
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

3.  Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.

Authors:  Michael Stahl; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Martin K Walz; Siegfried Seeber; Bodo Klump; Wilfried Budach; Reinhard Teichmann; Marcus Schmitt; Gerd Schmitt; Claus Franke; Hansjochen Wilke
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

4.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

5.  Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Authors:  Carlo Castoro; Marco Scarpa; Matteo Cagol; Alberto Ruol; Francesco Cavallin; Rita Alfieri; Gianpietro Zanchettin; Massimo Rugge; Ermanno Ancona
Journal:  Ann Surg Oncol       Date:  2011-05-10       Impact factor: 5.344

6.  The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Authors:  Björn L D M Brücher; Karen Becker; Florian Lordick; Ulrich Fink; Mario Sarbia; Hubert Stein; Raymonde Busch; Frank Zimmermann; Michael Molls; Heinz Höfler; Jörg R Siewert
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

7.  Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02).

Authors:  Christian Jost; Janek Binek; Jan C Schuller; Peter Bauerfeind; Urs Metzger; Baseli Werth; Juerg Knuchel; Jean-Louis Frossard; Philipp Bertschinger; Peter Brauchli; Christa Meyenberger; Thomas Ruhstaller
Journal:  Gastrointest Endosc       Date:  2010-03-20       Impact factor: 9.427

8.  Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.

Authors:  Paul M Schneider; Ralf Metzger; Hartmut Schaefer; Frank Baumgarten; Daniel Vallbohmer; Jan Brabender; Eva Wolfgarten; Elfriede Bollschweiler; Stephan E Baldus; Hans P Dienes; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

9.  Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Authors:  David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer.

Authors:  H Bartels; H J Stein; J R Siewert
Journal:  Br J Surg       Date:  1998-06       Impact factor: 6.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.